Evommune, Inc.
EVMN
Analytical Summary
Evommune, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.
3-Year Financial Trajectory
AnnualBullish Indicators
- No bullish signals detected.
Bearish Risks
- Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile
Health Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|
| Revenue Growth YoY (%) |
85.7%
Excellent
Excellent
Year-over-year change in total revenue
Optimal:
> 10%
vs Sector:
Above avg (+971%)
|
— | — |
| EPS Growth YoY (%) |
75.2%
Excellent
Excellent
Year-over-year change in earnings per share
Optimal:
> 10%
|
— | — |
| Net Income Growth YoY (%) |
-3.1%
Weak
Weak
Year-over-year change in net income |
— | — |
| FCF Growth YoY (%) |
67.7%
Excellent
Excellent
Year-over-year change in free cash flow |
— | — |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|
| Effective Tax Rate (%) (%) |
0.0%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
0.0%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
— |
| FCF / Net Income (x) |
1.11x
Fair
Fair
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.87x
Caution
Caution
Free cash flow relative to reported net income
Optimal:
> 1x
|
— |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|
| Return on Invested Capital (%) |
-39.4%
Weak
Weak
Return earned on debt + equity capital invested
Optimal:
> 10%
|
48.5%
Excellent
Excellent
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— |
| Return on Capital (%) (%) |
-36.0%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
-92.1%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
— |
| Return on Common Equity (%) (%) |
-33.5%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-323%)
|
46.3%
Excellent
Excellent
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Above avg (+209%)
|
— |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|
| Interest Coverage (x) |
-11581.57x
Weak
Weak
Operating income divided by interest expense
Optimal:
> 5x
|
-2059.21x
Weak
Weak
Operating income divided by interest expense
Optimal:
> 5x
|
— |
| Net Debt (USD) | $-44.06M | $-16.25M | — |
Secondary lens
Benchmark Lens
Compare EVMN against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare EVMN against peers after checking the statement evidence.
Signals
Key bullish and bearish indicators for EVMN
No bullish signals detected
Return on Common Equity (%) is in the bottom quartile
Percentile Rankings
How EVMN compares to all companies
Peer Comparison
EVMN vs similar peers
Compare EVMN with peers
Stack EVMN against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 4 days ago 3 years · 10 quarters